Medical Professionals
Publications, posters & presentations

Publications, posters & presentations -
our significant research

Filter

Filter

Clear filter
Research Area
Technology
Resource type
Category
117 results found
Aug 31, 2023
Publication
Novavax led
Preprint
COVID-19, Matrix-M™ adjuvant
XBB.1.5 Spike Protein COVID-19 Vaccine Induces Broadly Neutralizing and Cellular Immune Responses Against EG.5.1 and Emerging XBB Variants
View
Aug 30, 2023
Publication
Collaborative
Vaccine
COVID-19, Matrix-M™ adjuvant
Immunogenicity and safety of NVX-CoV2373 as a booster: A phase 3 randomized clinical trial in adults
View
Jun 16, 2023
Publication
Novavax included/third party
Journal of Infection
COVID-19, Matrix-M™ adjuvant
Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A randomised controlled trial
Angela M. Minassian, Eimear Kelly, et al.
View
May 21, 2023
Publication
Novavax led
The Journal of Infectious Diseases
COVID-19, Matrix-M™ adjuvant
Strong CD4+ T-Cell Responses to Ancestral and Variant Spike Proteins Are Established by NVX-CoV2373 SARS-CoV-2 Primary Vaccination
Louis Fries, Neil Formica, Raburn M Mallory, et al.
View
Apr 28, 2023
Publication
Novavax led
Human Vaccines & Immunotherapeutics
COVID-19, Matrix-M™ adjuvant
The Matrix-M™ adjuvant: A critical component of vaccines for the 21st century
Linda Stertman, Anna-Karin E. Palm, Behdad Zarnegar, et al.
View
Apr 26, 2023
Publication
Novavax led
JAMA Network Open
COVID-19, Matrix-M™ adjuvant
Safety, immunogenicity, and efficacy of the NVX-CoV2373 Covid-19 vaccine in adolescents a randomized clinical trial
Germán Áñez, Lisa M. Dunkle, Cynthia L. Gay, et al.
View
Mar 20, 2023
Publication
Novavax led
Pre-print
COVID-19, Matrix-M™ adjuvant
Immunogenicity and safety of NVX-CoV2373 as a Homologous or Heterologous booster: A phase 3 randomized clinical trial in adults
Fritz Raisera, Matthew Davisb, Jeffrey Adelglassc, et al.
View
Mar 19, 2023
Publication
Novavax led
Pre-print
COVID-19, Matrix-M™ adjuvant
NVX-CoV2373 vaccine efficacy against hospitalization: A post hoc analysis of the PREVENT-19 phase 3, randomized, placebo-controlled trial
Anthony M. Marchese, Xiang Zhou, John Kinol, et al.
View
Feb 28, 2023
Publication
Collaborative
Nature Communications
COVID-19, Matrix-M™ adjuvant
Immunogenicity and protection of a variant nanoparticle vaccine that confers broad neutralization against SARS-CoV-2 variants
James Logue, Robert M. Johnson, Nita Patel, et al.
View
Jan 25, 2023
Publication
Novavax led
Scientific Reports
COVID-19, Matrix-M™ adjuvant
Immunogenicity of a fourth Homologous dose of NVX-CoV2373
Katia Alves, Joyce S. Plested, Shirley Galbiati, et al.
View